Wire · opportunities
FDA Approves Labcorp's PGDx Elio Tissue Complete CDx for Advanced Melanoma
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 25 August 2026 · Fusion42 review
The FDA has approved Labcorp's PGDx elio tissue complete CDx as a companion diagnostic test to identify BRAF V600E/V600K mutations in advanced melanoma patients, aiding in the timely selection of targeted BRAF and BRAF/MEK therapies. The test uses a 505-gene NGS panel with strong analytical performance, enabling rapid in-house testing in hospitals for precise and quick treatment decisions.
This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it.
◆ ◆ The Wire takeaway
You can now offer clinicians a rapid, hospital-deployable test that clearly identifies melanoma patients eligible for BRAF-targeted therapies. This opens direct pathways to hospitals demanding quick genetic insights for personalised cancer treatment.
◆ Coverage
3 sources · 10 Aug 2026
◆ Related on Wire
◆ Topics